Kraig Biocraft Laboratories has spent years engineering silkworms to spin spider silk, a fibre prized for strength and toughness. In the past two months it has shipped its first commercial yarn order and run all three of its rearing centres in Vietnam, but its latest accounts show no revenue, a large deficit and a going concern warning.
What the company does
Kraig Biocraft Laboratories, known as Kraig Labs, is a US biotechnology company quoted on the OTCQB under the ticker KBLB. Its research headquarters is a leased 5,000-square-foot site in Lansing, Michigan, and its press releases are datelined Ann Arbor.
The company's technology is a genetically engineered silkworm that carries key spider silk proteins. The idea is to use an insect the silk industry already rears in large numbers to produce a recombinant spider silk.
Production takes place in Vietnam through its subsidiary Prodigy Silk, which took over production work after an earlier subsidiary, Prodigy Textiles, was dissolved in January 2026. The company leases facilities and land in Lam Dong province.
Kim Thompson is the founder and chief executive.
Kraig Biocraft Laboratories: share price, chart and news

From the lab to first sales
Kraig has issued a stream of updates since late summer. All are company statements, and few include figures that can be checked.
Recent company announcements
- 24 August: silk output up more than 30% in what it calls its most technically challenging season; it later said this beat a June cycle of nearly 2.5 tonnes of cocoons
- 24 September: completion of what it calls a functional and living atlas gene library
- 29 September: first commercial order of spider silk yarn shipped to an unnamed performance sports brand
- 5 October: full production at all three rearing centres, run on staggered cycles
- 12 October: filing for an expanded investment licence for Prodigy Silk, with no amount disclosed
- 26 October: a performance yarn development programme, and samples sent to an unnamed developer of yarn spinning equipment that has worked with aerospace manufacturers
- 2 November: an early-stage programme to test diet additives that could raise spider silk protein output
The yarn order matters most, because it is the first commercial sale of its yarn that the company has reported. But Kraig disclosed no quantity, price or customer name, and Thompson said the volume was small by design.
The company has said it intends to pursue several commercial paths, including partnerships with brands, textile mills and manufacturers, and its own apparel work. "Spider silk is a material that will earn its place through performance," Thompson said in October.
The latest numbers and how Kraig funds itself
Kraig's most recent quarterly report, filed with the US Securities and Exchange Commission on 13 August, covers the six months to 30 June 2026.
| Results, six months to 30 June | Figure |
|---|---|
| Revenue, 2026 | $0 |
| Operating expenses, 2026 | $1,528,933 |
| Net loss, 2026 | $1,852,255 |
| Net loss, same period of 2025 | $1,326,166 |
| Balance sheet at 30 June 2026 | Figure |
|---|---|
| Cash and cash equivalents | $3,391,646 |
| Total assets | $4,271,792 |
| Total liabilities | $11,022,908 |
| Stockholders' deficit | $6,751,116 |
| Working capital deficiency | $7,326,899 |
| Class A shares outstanding (13 August) | 1,115,334,070 |
Second-quarter net loss was $909,535, against $726,133 a year earlier. In the first half, general and administrative costs were $869,947, the chief executive's salary $387,219, professional fees $140,697 and research and development $131,070.
The company also holds 110 ounces of gold bullion, carried at a fair value of $440,652 at 30 June.
Funding at a glance
- $10m maximum share sales under its standby equity agreement
- $2.77m raised by selling 25.4m shares in the first half
- $1.49m note payable to the founder, due on demand
Kraig pays its way mainly by selling new shares. Under a standby equity purchase agreement signed in January 2025, it can sell up to $10m of common stock to an investor. In the first half of 2026 it sold 25,364,093 shares for $2,772,547, after raising $1,925,702 this way in all of 2025.
It also owes money to its founder. The 10-Q lists a $1,492,000 note payable to the founder and chief executive at 3% interest, unsecured and due on demand, and $8.77m of accounts payable and accrued expenses owed to a related party.
There were also 58.3 million warrants and 37.5 million options outstanding at 30 June, which could add further shares if exercised.
Main risks
The filing states that the working capital and stockholders' deficiencies, together with cash used in operations, raise substantial doubt about the company's ability to continue as a going concern. That is the clearest risk: Kraig needs outside money to keep operating.
Dilution follows from that. Each share sale under the equity agreement adds to a share count already above 1.1 billion, and the outstanding warrants and options add more.
The commercial case is unproven. The company has shipped a small first order, but has not shown repeat orders, prices or margins, and it has not published independent test data on its yarn.
Production depends on farming living silkworms in Vietnam, which brings seasonal, biological and country risks, as well as reliance on licences there. Shares quoted on the OTCQB can also trade thinly and move sharply.
What to watch next
| Event | Expected timing |
|---|---|
| 10-Q for the quarter to 30 September 2026 | Mid-November 2026 |
| Any revenue from yarn sales in its accounts | Next quarterly reports |
| Follow-on orders from the sports brand pilot | No date given |
| Outcome of the expanded investment licence filing | No date given |
| Results from the diet additive programme | No date given |
The September-quarter filing will show whether the first yarn shipment produced any revenue and how much cash remained after the summer's production push.
Sources
- Kraig Biocraft Laboratories: Form 10-Q for the quarter ended 30 June 2026 (SEC, 13 August 2026)
- Kraig Biocraft Laboratories: news releases
- Kraig Biocraft Laboratories: first commercial spider silk yarn order (29 September 2026)
- Kraig Biocraft Laboratories: full production across three production centres (5 October 2026)
- Kraig Biocraft Laboratories: expanded investment licence filing (12 October 2026)
- Kraig Biocraft Laboratories: performance yarn development programme (26 October 2026)
- Kraig Biocraft Laboratories: dietary additive programme (2 November 2026)








